Ono Pharmaceutical Co., Ltd. (OPHLY)
| Market Cap | 7.08B +27.1% |
| Revenue (ttm) | 3.10B +1.5% |
| Net Income | 469.07M +77.6% |
| EPS | 1.00 +77.8% |
| Shares Out | n/a |
| PE Ratio | 15.09 |
| Forward PE | n/a |
| Dividend | 0.17 (3.24%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 5,200 |
| Open | 4.970 |
| Previous Close | 5.030 |
| Day's Range | 4.940 - 4.970 |
| 52-Week Range | 3.710 - 5.750 |
| Beta | 0.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabet... [Read more]
Financial Performance
In fiscal year 2026, Ono Pharmaceutical's revenue was 515.79 billion, an increase of 5.94% compared to the previous year's 486.87 billion. Earnings were 69.77 billion, an increase of 39.40%.
Financial numbers in JPY Financial StatementsNews
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that it has entered into a drug dis...
Ono Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory Diseases
OSAKA, Japan & BOSTON--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced today that it has entered into a drug discovery par...
Ono Pharmaceutical Quarterly report: Q1 2027
Ono Pharmaceutical has published its Q1 2027 quarterly earnings report on July 31, 2026.
Ono Pharmaceutical Slides: Q1 2027
Ono Pharmaceutical has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 31, 2026.
Ono Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientist
OSAKA, Japan and SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (TYO: 4528, "Ono") and Phylo, Inc. ("Phylo") today announced a collaboration that brings Biomni...
Ono Pharmaceutical Slides: Investor presentation
Ono Pharmaceutical has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced the results of the phase 2 clinical study (ONO-4578-08...
Ono Pharmaceutical Quarterly report: Q4 2026
Ono Pharmaceutical has published its Q4 2026 quarterly earnings report on May 8, 2026.
Ono Pharmaceutical Slides: Q4 2026
Ono Pharmaceutical has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 8, 2026.
Ono Pharma Announces Upcoming Presentations at the ASCO 2026 Annual Meeting
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceuticals Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced two upcoming presentations at the 2026 American Soci...
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that Ono submitted an application for the manufacturing and ma...
Ono Pharmaceutical Slides: Investor presentation
Ono Pharmaceutical has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
OSAKA, Japan & MONTREAL--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that it has entered into an agreement to expand the drug ...
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announc...
Ono Pharmaceutical Quarterly report: Q3 2026
Ono Pharmaceutical has published its Q3 2026 quarterly earnings report on February 1, 2026.
Ono Pharmaceutical Slides: Q3 2026
Ono Pharmaceutical has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 1, 2026.
Ono Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference
The presentation outlined a robust global growth strategy, emphasizing the Deciphera acquisition, OPDIVO life cycle management, and a strong pipeline with multiple high-potential launches planned through 2031. Financial outlook remains positive, with sustained R&D investment and confidence in overcoming the OPDIVO patent cliff.
Ono Pharmaceutical Slides: 44th Annual J.P. Morgan Healthcare Conference
Ono Pharmaceutical has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical...
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announc...
Deciphera Announces the Opening of a New Office in Zug, Switzerland
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the opening of a new 733-square-mete...
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline pro...
Ono Pharmaceutical Quarterly report: Q2 2026
Ono Pharmaceutical has published its Q2 2026 quarterly earnings report on October 30, 2025.
Ono Pharmaceutical Slides: Q2 2026
Ono Pharmaceutical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 30, 2025.
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety res...